GHRH analog peptide (previously FDA-approved; discontinued)
GHRH 1-29
A short GHRH analog that stimulates endogenous GH release; previously FDA-approved but discontinued commercially.
- Evidence:
- Moderate human evidence
- Status:
- Withdrawn / restricted
- Reviewed:
- 2026-08-03
Also known as: GHRH 1-29, Geref
What is GHRH 1-29?
A short GHRH analog that stimulates endogenous GH release; previously FDA-approved but discontinued commercially.
This profile is educational. It organizes publicly discussed research context for GHRH 1-29 and related naming aliases — it is not a treatment guide.
Proposed mechanism
Binds GHRH receptors on pituitary to stimulate pulsatile growth hormone secretion.
Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.
Current research notes
Human evidence grade: Moderate human evidence
Preclinical evidence grade: Strong human evidence
Sermorelin (Geref) was FDA approved for pediatric GH deficiency diagnosis but discontinued for commercial reasons, not necessarily safety. Still compounded and studied in adult GH insufficiency research. Human evidence exists for GH stimulation. WADA prohibited.
Key uncertainties
- Clinical role vs rhGH and newer secretagogues
Research areas being studied
- GH deficiency
- Anti-aging research
- Body composition
Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.
Safety & side-effect notes
Reported or discussed adverse effects
- Injection-site reactions
- Flushing
- Headache
- Dizziness
Additional risks & considerations
- GH-axis effects
- Compounding quality variability
- WADA prohibited
Regulatory status
Withdrawn / restricted
Previously FDA approved; discontinued. Compounded in limited contexts.
Regulatory framing here is educational and can lag policy changes. Check official sources for current status.
Frequently asked questions
What is GHRH 1-29?
A short GHRH analog that stimulates endogenous GH release; previously FDA-approved but discontinued commercially.
How does GHRH 1-29 work (proposed mechanism)?
Binds GHRH receptors on pituitary to stimulate pulsatile growth hormone secretion.
What is GHRH 1-29 being researched for?
GHRH 1-29 has been discussed in research contexts including: GH deficiency, Anti-aging research, Body composition.
What does current evidence say about GHRH 1-29?
Moderate human evidence. Sermorelin (Geref) was FDA approved for pediatric GH deficiency diagnosis but discontinued for commercial reasons, not necessarily safety. Still compounded and studied in adult GH insufficiency research. Human evidence exists for GH stimulation. WADA prohibited.
What safety considerations are noted for GHRH 1-29?
Reported or discussed considerations include: Injection-site reactions; Flushing; Headache; Dizziness; GH-axis effects; Compounding quality variability; WADA prohibited. This is educational information, not medical advice.
Is GHRH 1-29 FDA approved?
Withdrawn / restricted. Previously FDA approved; discontinued. Compounded in limited contexts.
References & sources
- Walker RF (2006). Sermorelin acetate in GH deficiency — Clin Interv Aging. Evidence type: review.
Prefer interactive tools? Open the PepGuide library entry for GHRH 1-29 or ask PepGuide AI.
Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.